Recall Enforment Report D-0045-2025

Recall Details

Drug Recall Enforcement Report Class III voluntary initiated by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories, originally initiated on 11-05-2024 for the product Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, Distributed by: MAJOR Pharmaceuticals, Livonia, MI, 48152, USA, NDC 0904-6441-61. The product was recalled due to failed impurities/degradation specifications; during routine stability testing for impurities.. The product was distributed nationwide and the recall is currently ongoing.

Field Name Field Value
Event ID 95700 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-0045-2025 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern Nationwide in the US. What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, Distributed by: MAJOR Pharmaceuticals, Livonia, MI, 48152, USA, NDC 0904-6441-61.
Reason For Recall Failed Impurities/Degradation Specifications; during routine stability testing for impurities. What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 25814 tablets Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 11-20-2024
Recall Initiation Date 11-05-2024 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Initial Firm Notification Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Code Info Lot#: T04888, Exp 11/2024; T04946, Exp 12/2024; T04970, Exp 07/2025 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 0904-6440-61; 0904-6441-61; 0904-6442-61; 0904-6443-10; 0904-6443-61
Status Ongoing

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
0904-6440Hydralazine Hydrochloride Major Pharmaceuticals
0904-6441Hydralazine Hydrochloride Hydralazine HydrochlorideTablet, Film CoatedOralMajor PharmaceuticalsHuman Prescription Drug
0904-6442Hydralazine Hydrochloride Major Pharmaceuticals
0904-6443Hydralazine Hydrochloride Major Pharmaceuticals